According to them, their compound showed reduced kidney uptake (~7 %IA/g at 24 h p.i.), increased tumor uptake (~35 %IA/g at 24 h p.i.), and longer tumor retention relative to other PSMA ligands, like PSMA-617, CTT1403, PSMA-Alb-02, and PSMA-Alb-56 [139]. This evidence concerns the gene FOLH1 and neoplasm.